Price
$93.45+13.43%Social Signal Score
Analyst Ratings
51 analysts52-week range
- Last close
- $93.45
- Off 52w high
- -11.3%
- 200-day average
- $89.38
- vs 200-day
- +4.6%
Revenue
$9.76B+32.83%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Geoffrey Straub Martha
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 95,000
- Beta
- 0.57
- Country
- IE
- Piotroski score
- 9 / 9 (Strong)
- Altman Z-score
- 2.88
Financials
Revenue
$9.76B+32.8%Net Income
$1.47B+31.8%EBITDA
$1.96B-11.5%Free Cash Flow
$1.29B+7.1%EPS (diluted)
$1.14+42.5%Shares Outstanding (diluted)
1.29B-7.7%Operating Expenses
$3.97BCash & Debt
$8.82BReturn of Capital
$1.19BRevenue by Segment (annual)
$36.19BDividend per Share
$0.72Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $36.36B | $4.80B | $3.75 |
| 2025 | $33.54B | $4.66B | $3.63 |
| 2024 | $32.36B | $3.68B | $2.77 |
| 2023 | $31.23B | $3.76B | $2.83 |
| 2022 | $31.69B | $5.04B | $3.75 |
| 2021 | $30.12B | $3.61B | $2.68 |
| 2020 | $28.91B | $4.79B | $3.57 |
| 2019 | $30.56B | $4.63B | $3.44 |
| 2018 | $29.95B | $3.10B | $2.29 |
| 2017 | $29.71B | $4.03B | $2.92 |
| 2016 | $28.83B | $3.54B | $2.51 |
| 2015 | $20.26B | $2.67B | $2.44 |
| 2014 | $17.00B | $3.06B | $3.06 |
| 2013 | $16.59B | $3.47B | $3.40 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MDT's reported EPS growth of 0.8% a year over 13 years.
- EPS in 5 years
- $3.90
- Implied price
- $85.73
- Return from $86.38
- -0.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $42.62 — -50.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -9.2% | -15.6% | -12.7% | -10.1% | -7.7% | -5.6% |
| -4.2% | -11.0% | -7.8% | -5.1% | -2.6% | -0.4% |
| 0.8% | -6.3% | -3.0% | -0.2% | 2.4% | 4.8% |
| 5.8% | -1.7% | 1.8% | 4.8% | 7.5% | 10.0% |
| 10.8% | 3.0% | 6.6% | 9.8% | 12.6% | 15.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80+14.29%Social Signal Score
Mentions (53)
- Newszacks.com·14h ago·Positive
Medtronic (MDT) Outperforms Broader Market: What You Need to Know Medtronic (MDT) concluded the recent trading session at $87.97, signifying a +1.84% move from its prior day's close.
View source ↗ - News247wallst.com·3d ago·Neutral
Medtronic's 49-Year Dividend Streak Faces a New Challenge: Is Growth Finally the Real Story? Medtronic has raised its dividend for 49 straight years while the stock quietly lost a fifth of its value, but something in the operating room just changed the entire conversation about why investors should own it.
View source ↗ - Newsbarrons.com·3d ago·Neutral
Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its Allure The tax-free exchange offer allows Medtronic investors to swap their shares for MiniMed shares held by Medtronic in what Wall Street calls a split-off.
View source ↗ - Newsprnewswire.com·4d ago·Positive
…d physician adoption of Medtronic solutions addressing urge urinary incontinence and hypertension GALWAY, Ireland, Oct. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its technologies, which represent important long-term growth opportunities for Medtronic: Altaviva™ implantable tibial neuromodulation device for t…
View source ↗ - Newszacks.com·4d ago·Neutral
Why Is Medtronic (MDT) Down 6.4% Since Last Earnings Report? Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsfool.com·5d ago·Positive
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade. Johnson & Johnson has significantly outperformed Medtronic over the past decade. Much of its outperformance started with its 2021 decision to spin off its consumer healthcare business.
View source ↗ - Newszacks.com·6d ago·Negative
Medtronic (MDT) Registers a Bigger Fall Than the Market: Important Facts to Note In the closing of the recent trading day, Medtronic (MDT) stood at $87.09, denoting a -2.69% move from the preceding trading day.
View source ↗ - Newsfool.com·9d ago·Positive
Medtronic's High Dividend Yield Gets Little Attention on Wall Street -- Should You Buy the Stock Anyway? At the current share price, Medtronic's dividend yield is 3.2%. The company has increased its payouts for 49 consecutive years.
View source ↗ - Newszacks.com·12d ago·Negative
Here's Why Medtronic (MDT) Fell More Than Broader Market Medtronic (MDT) reached $89.3 at the closing of the latest trading day, reflecting a -1.62% change compared to its last close.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Medtronic: Buy The 3% Yield And Strong Free Cash Flow Growth Medtronic is initiated with a buy rating and a $106.33 price target, implying 17% upside and a 3% dividend yield. Q1 FY27 results exceeded expectations, with normalized revenue growth of 7% and notable strength in Cardiovascular and Neuroscience segments. Guidance was raised for revenue and EPS, but margin expansion is expected to materialize gradually as product mix shifts toward higher-margin recurring revenues.
View source ↗ - Newsseekingalpha.com·13d ago·Negative
Medtronic: The Turnaround Is No Longer Quiet Medtronic delivered solid Q1 FY27 results, with organic revenue growth of ~7%, and raised full-year guidance to 7.25–7.75%. Newer businesses, especially Cardiac Ablation Solutions, are now meaningful contributors, supporting a more robust growth profile for MDT. The MiniMed separation will make MDT smaller but more profitable, with expected margin improvements and a sharper focus on core segments.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Medtronic: Don't Miss Out On This Dividend Aristocrat Deal Now Medtronic has trounced the S&P 500 index in recent months. The company's strong showing in Q1 2027 prompted it to raise its non-GAAP EPS guidance for FY 2027. Medtronic's interest coverage ratio and net debt to EBITDA ratio are both healthy.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies
View source ↗ - Newsprnewswire.com·20d ago·Negative
…in more than 45 million procedures worldwide is now cleared for robotic-assisted surgery in the U.S. GALWAY, Ireland, Sept. 16, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) has cleared the LigaSure™ RAS Maryland jaw device for use with the Hugo™ robotic-assisted surgery (RAS) system.
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
Medtronic Sees AI, Ablation and Targeted M&A Fueling Growth Medtronic NYSE: MDT Chief Financial Officer Thierry Piéton said the medical-device maker's focus on acute procedures, expanding innovation pipeline and increased use of targeted acquisitions are supporting its recent growth momentum.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Medtronic plc (MDT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Medtronic plc (MDT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·22d ago·Positive
…s with option for a generally tax-free exchange for U.S. federal income tax purposes GALWAY, Ireland, Sept. 14, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced that it has commenced an exchange offer to split off at least 80.1% of the shares of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED).
View source ↗ - Newsprnewswire.com·22d ago·Negative
…t it has filed a Form S-4 Registration Statement today with the Securities and Exchange Commission (the "SEC") in connection with Medtronic plc's ("Medtronic"; NYSE: MDT) offer to exchange up to 225,361,295 shares of MiniMed common stock, representing 80.1% of the total outstanding shares of MiniMed common stock, for outstanding Medtronic ordinary shares that are validly tendered and not validly withdrawn.
View source ↗ - News247wallst.com·22d ago·Positive
Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one.
View source ↗ - Newszacks.com·26d ago·Positive
Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.
View source ↗ - Newsmarketbeat.com·27d ago·Neutral
Medtronic Touts AI, Robotics and Ablation Growth at Wells Fargo Conference Medtronic NYSE: MDT executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.
View source ↗ - Newszacks.com·27d ago·Positive
Is Medtronic Worth Buying as Growth Improves but Risks Stay Elevated? MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.
View source ↗ - Newszacks.com·32d ago·Positive
Why Medtronic (MDT) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·33d ago·Neutral
MDT Q1 Earnings Call Focuses on Broad Growth, Raised Guidance Medtronic raises its fiscal 2027 outlook as growth broadens across major franchises and newer platforms, with robotics and ablation investments advancing.
View source ↗ - Newszacks.com·33d ago·Positive
Why Medtronic (MDT) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsbenzinga.com·34d ago·Positive
Medtronic Analysts Raise Their Forecasts After Upbeat Q1 Earnings Medtronic PLC (NYSE:MDT) on Tuesday reported better-than-expected first-quarter financial results and raised its FY27 adjusted EPS guidance.
View source ↗ - Newsprnewswire.com·34d ago·Neutral
Cornerstone Robotics ogłasza strategiczne partnerstwo z Medtronic mające na celu zwiększenie dostępu do chirurgii robotycznej na świecie /PRNewswire/ -- Cornerstone Robotics, innowacyjna firma z branży robotyki chirurgicznej założona i mająca siedzibę w Hongkongu, ogłosiła dziś strategiczne
View source ↗ - Newsyoutube.com·34d ago·Positive
Medtronic CEO Martha on beating estimates in Q1: Driven by growth across many of our businesses Geoff Martha, Medtronic CEO, joins 'Squawk on the Street' to discuss shares rising Tuesday after the company announced a $700 million investment in Cornerstone Robotics, a robotic surgical company.
View source ↗ - Newsseekingalpha.com·34d ago·Positive
Medtronic plc (MDT) Q1 2027 Earnings Call Transcript Medtronic plc (MDT) Q1 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·34d ago·Positive
Medtronic's Stars Are Aligning for a Price Recovery Medtronic NYSE: MDT is a good buy in late 2026 because stars such as value, growth, guidance, partnerships, and dividends are aligning. They point to sustained outperformance and potential acceleration but, more importantly, to robust capital returns.
View source ↗ - Newszacks.com·34d ago·Positive
Medtronic Q1 Earnings & Revenues Top Estimates, Stock Up in Pre-Market MDT beats Q1 earnings and revenue estimates as broad-based growth drives shares higher and prompts a fiscal 2027 guidance boost.
View source ↗ - Newszacks.com·34d ago·Neutral
Here's What Key Metrics Tell Us About Medtronic (MDT) Q1 Earnings Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsmarketbeat.com·34d ago·Neutral
Medtronic Q1 Earnings Call Highlights Medtronic NYSE: MDT reported fiscal 2027 first-quarter revenue of $9.8 billion and adjusted earnings per share of $1.45, as the medical-device maker cited broad-based demand, commercial execution and momentum in several growth platforms.
View source ↗ - Newswsj.com·35d ago·Neutral
Medtronic Lifts Outlook, Invests Over $700 Million in Heart Tech & Robotics Medtronic raised its outlook for the year after posting higher fiscal first-quarter profit and sales, driven by broad-based demand and contributions from newer growth platforms.
View source ↗ - Newsbarrons.com·35d ago·Neutral
Medtronic Stock Rises on Better-Than-Expected Earnings and $700 Million Investment in a Robot Surgeon Medtronic stock advances after the company posts better-than-expected quarterly earnings, raises revenue guidance, and announces a $700 million investment.
View source ↗ - Newsprnewswire.com·35d ago·Positive
…s, new growth platforms, and recent portfolio investments support the long-term growth trajectory GALWAY, Ireland, Sept. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2027 (FY27), which ended July 31, 2026.
View source ↗ - Newsprnewswire.com·35d ago·Neutral
Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR GALWAY, Ireland and REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and Pi-Cardia Ltd.
View source ↗ - Newsbenzinga.com·35d ago·Neutral
Medtronic, Dell and 3 Stocks to Watch Heading Into Tuesday With U.S. stock futures trading slightly lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
View source ↗ - Newszacks.com·35d ago·Neutral
Brokers Suggest Investing in Medtronic (MDT): Read This Before Placing a Bet The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
View source ↗ - Newsbenzinga.com·39d ago·Neutral
Medtronic Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Medtronic plc (NYSE:MDT) will release its first earnings report before the opening bell on Tuesday, Sept. 1.
View source ↗ - Newszacks.com·39d ago·Positive
Is This the Right Time to Hold Medtronic Stock in Your Portfolio? MDT's Cardiovascular gains and renal denervation growth offer upside, but tariffs and currency headwinds cloud its outlook.
View source ↗ - Newszacks.com·39d ago·Neutral
Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2026.
View source ↗ - Newszacks.com·40d ago·Positive
MDT's Q1 Earnings on Deck: How Should You Play the Stock Now? Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.
View source ↗ - Newszacks.com·41d ago·Positive
Medtronic (MDT) Stock Dips While Market Gains: Key Facts In the latest trading session, Medtronic (MDT) closed at $91.22, marking a -1.81% move from the previous day.
View source ↗ - Newsseekingalpha.com·45d ago·Neutral
Medtronic: The CAS Catalyst Can Close A 27% Peer Discount Medtronic is rated a 'Buy,' favored for its attractive valuation and potential upside from its CAS segment despite recent underperformance. CAS, now 5-6% of revenue, is annualizing above $2B and could reach $3B in a few years if execution remains strong. Guidance targets 6.75%-7.25% organic growth and $5.90-$6.00 EPS, but calendar effects and MiniMed separation timing are key variables.
View source ↗ - Newsprnewswire.com·46d ago·Neutral
Medtronic announces cash dividend for second quarter of fiscal year 2027 GALWAY, Ireland, Aug. 20, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 20, 2026, approved the company's cash dividend for the second quarter of fiscal year 2027 of $0.72 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in June 2026.
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Medtronic: Expecting Strong Revenue Growth In Fiscal Q1 Medtronic is reiterated as a "Buy," with shares offering over 10% fundamental upside and attractive valuation metrics. Q4 delivered 6.6% organic revenue growth—best in a decade—driven by double-digit gains in the Cardiovascular and Diabetes segments. FY 2027 guidance targets 6.75%-7.25% organic revenue growth and $5.90-$6.00 non-GAAP EPS, despite tariff and competitive headwinds.
View source ↗ - Newszacks.com·48d ago·Neutral
Medtronic (MDT) Advances While Market Declines: Some Information for Investors In the most recent trading session, Medtronic (MDT) closed at $92.09, indicating a +1.64% shift from the previous trading day.
View source ↗ - Newszacks.com·48d ago·Positive
MDT vs. A: Which Stock Should Value Investors Buy Now? Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Agilent Technologies (A). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newszacks.com·53d ago·Neutral
Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy? The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
View source ↗ - Newszacks.com·56d ago·Negative
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know In the closing of the recent trading day, Medtronic (MDT) stood at $89.41, denoting a +2.58% move from the preceding trading day.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Medtronic: Buy This Undervalued Dividend Aristocrat Before The Market Catches On Medtronic is rated 'Buy' for its compelling combination of income, growth, and value. MDT's growth is led by cardiac ablation with 124% U.S. segment growth and rapid expansion of the Hugo robotic surgery platform. Management guides for 11.75% organic revenue growth in Q1 2027, with CAS expected to outpace the market and Symplicity renal denervation gaining traction.
View source ↗ - Newsfool.com·58d ago·Positive
Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now? Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market.
View source ↗
Earnings
Tue, Nov 17(in 6 weeks)
Consensus estimate $1.34 per share
Typical surprise +2.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Sep 1$1.45 vs $1.39beat
- Wed, Jun 3$1.55 vs $1.54beat
- Tue, Feb 17$1.36 vs $1.34beat
- Tue, Nov 18$1.36 vs $1.31beat
- Tue, Aug 19$1.26 vs $1.23beat
- Wed, May 21$1.62 vs $1.58beat
Estimates and results for MDT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MDT officers and directors.
- Bought
- —
- Sold
- $5.8m
0 trades
8 trades
- Kiil Harry Skipsold
- Walter Matthew R.sold
- Kiil Harry Skipsold
- Kiil Harry Skipsold
- Kiil Harry Skipsold
- Kiil Harry Skipsold
- Kiil Harry Skipsold
- Kiil Harry Skipsold
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 2, 2026 (9d later)Sell$15,001 - $50,000
- Rich McCormickhouse · GA06 · disclosed Aug 17, 2026 (18d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Aug 6, 2026 (456d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (709d later)Sell$15,001 - $50,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2026 (25d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Apr 6, 2026 (17d later)Sell$15,001 - $50,000
- Julie Johnsonhouse · TX32 · disclosed Jan 16, 2026 (29d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (29d later)Sell$1,001 - $15,000
- Rich McCormickhouse · GA06 · disclosed Dec 10, 2025 (35d later)Buy$1,001 - $15,000
- Rich McCormickhouse · GA06 · disclosed Sep 17, 2025 (917d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Sep 12, 2025 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 10, 2025 (13d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (46d later)Sell$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Apr 29, 2025 (21d later)Sell$1,001 - $15,000
- George Whitesideshouse · CA27 · disclosed Apr 23, 2025 (30d later)Sell$50,001 - $100,000
- Bruce Westermanhouse · AR04 · disclosed Apr 17, 2025 (28d later)Sell$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed Apr 17, 2025 (44d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.